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Increase in DNA vaccine efficacy by virosome delivery
and co-expression of a cytolytic protein
Tessa Gargett1,5, Branka Grubor-Bauk1, Darren Miller2, Tamsin Garrod1, Stanley Yu1, Steve Wesselingh3,
Andreas Suhrbier4 and Eric J Gowans1
The potential of DNA vaccines has not been realised due to suboptimal delivery, poor antigen expression and the lack of
localised inflammation, essential for antigen presentation and an effective immune response to the immunogen. Initially,
we examined the delivery of a DNA vaccine encoding a model antigen, luciferase (LUC), to the respiratory tract of mice by
encapsulation in a virosome. Virosomes that incorporated influenza virus haemagglutinin effectively delivered DNA to cells in
the mouse respiratory tract and resulted in antigen expression and systemic and mucosal immune responses to the immunogen
after an intranasal (IN) prime/intradermal (ID) boost regimen, whereas a multidose ID regimen only generated systemic
immunity. We also examined systemic immune responses to LUC after ID vaccination with a DNA vaccine, which also encoded
one of the several cytolytic or toxic proteins. Although the herpes simplex virus thymidine kinase, in the presence of the
prodrug, ganciclovir, resulted in cell death, this failed to increase the humoral or cell-mediated immune responses. In contrast,
the co-expression of LUC with the rotavirus non-structural protein 4 (NSP4) protein or a mutant form of mouse perforin,
proteins which are directly cytolytic, resulted in increased LUC-specific humoral and cell-mediated immunity. On the other
hand, co-expression of LUC with diphtheria toxin subunit A or overexpression of perforin or NSP4 resulted in a lower level of
immunity. In summary, the efficacy of DNA vaccines can be improved by targeted IN delivery of DNA or by the induction of cell
death in vaccine-targeted cells after ID delivery.
Clinical & Translational Immunology (2014) 3, e18; doi:10.1038/cti.2014.13; published online 27 June 2014
DNA vaccines are appealing vaccine candidates as they are simple and
inexpensive to manufacture and also highly stable. These character-
istics make DNA vaccines an ideal technology particularly for use in
developing countries where inexpensive vaccines are required most
urgently. In practical terms, vaccines may be required to elicit
systemic or mucosal immune responses.
However, the administration of DNA vaccines to mucosal surfaces
is generally ineffective because the DNA is rapidly degraded before it
is taken up by epithelial cells.1,2 Nevertheless, mucosal delivery
induces a more relevant immune response at sites where
transmission of pathogens, including human immunodeficiency
virus (HIV), is common. Novel vaccine strategies to elicit
protection against pathogens that are transmitted by contact with
mucosal surfaces should therefore focus on inducing systemic and
mucosal immune responses by delivering antigen to the mucosa. By
targeting mucosal surfaces,3 intranasal (IN) immunisation generates
immune responses not only in distant mucosal tissues (for example,
cervicovaginal mucosa) but also systemically. Consequently pan-
mucosal immune responses generated at distal sites such as the
genital tract represent an important strategy for the prevention of
sexually transmitted infections.4 Influenza virus virosomes have been
used previously to deliver peptide or protein5,6 and DNA vaccines7,8
in an attempt to increase the efficacy of delivery and are attractive
because B95% of injected DNA remains extracellular9 and
consequently is degraded and fails to contribute to vaccine efficacy,
whereas DNA complexed with polyethyleneimine has been used for
IN delivery to improve uptake and overcome mucosal degradation of
the DNA.10 Therefore, virosome encapsulation may offer an improved
delivery strategy for a mucosa-targeted vaccine. Influenza virosomes
use a combination of lipid molecules and influenza envelope proteins
(including hemagglutinin), maintain membrane binding and
endosomal membrane fusion properties of the virus and provide
targeted delivery to cells. In addition, several other strategies have
been used to increase the cellular uptake of DNA after vaccination,
including the use of gene guns and more recently, electroporation
(reviewed in Saade and Petrovsky11). Intradermal (ID), rather than
intramuscular, delivery of DNA is more effective,12 likely because the
dermis/subdermis contain a higher proportion of antigen-presenting
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cells, including dendritic cells (DC), than muscle.13 DC are the major
antigen-presenting cells able to prime naı¨ve T cells, which is the
primary aim of vaccination. Although direct presentation of epitopes
results from endogenous expression of the immunogen in DC, cross
presentation is likely to represent a more common pathway to induce
immunity to viruses which do not directly infect DC.14 Thus, a
successful DNA vaccine delivery must target DC and/or otherwise
direct the immunogen to cross-presenting DC. Cellular necrosis has
recently been identified as a key pathway that allows endogenous
antigen to be taken up by DC for cross presentation, and therefore the
induction of cell death following vaccination has the potential to
enhance vaccine antigen cross presentation.15,16 A previous study17
used Fas to induce apoptosis and improve the immune response to an
HIV-1 Env DNA vaccine, although the genes were co-administered on
separate plasmids, with the result that cell death was not specifically
targeted to antigen-positive cells. Similarly, prior intramuscular
administration of cardiotoxin before administration of a DNA
vaccine was used to induce sterile inflammation and DC
recruitment at the site of vaccination.18 These studies indicate that
a vaccination strategy, which induces cell death, may enhance
inflammation and subsequent vaccine efficacy.
Consequently, the aims of this study were to identify new
techniques to improve DNA vaccination and to this end we examined
the efficacy of DNA vaccination after (i) IN delivery by influenza
virosomes to protect DNA from degradation and (ii) ID delivery of
vaccines that encode an immunogen and a cytolytic or toxic protein
to increase the efficacy of DNA vaccination by inducing cell death
in vaccine-targeted cells, resulting in cross presentation of the
immunogen.
RESULTS
Mucosal immunity after IN delivery of DNA
Preliminary in vitro studies showed that haemagglutinin (HA)-
containing virosomes delivered DNA to HEK293T cells equally
effectively as commercially available transfection reagents and was
more effective than these agents in delivering DNA to the mucin-
producing A549 cell line (data not shown). IN delivery of the
virosomes to C57Bl/6 mice showed that HAþ virosomes were able
to effectively deliver DNA to the nasal epithelia (Figure 1), as
determined by live imaging of luminescence, whereas naked DNA
was unable to do so. However, there was considerable mouse–mouse
variability in luciferase (LUC) expression, which may be due to the
administration technique, which involves placing drops of liquid on
the nares and allowing the mouse to inhale. The level of anaesthesia
affects the respiration rate and the efficiency of vaccine delivery, and
lightly anesthetised mice may swallow, rather than inhale, an aliquot
of the vaccine dose. Pretreatment of the nasal passages with lysopho-
sphatidycholine, a surfactant that has been used to improve IN
delivery by others,17 did improve transfection efficiency (data not
Figure 1 (A) In vivo expression of LUC on day 3 post vaccination. C57Bl/6
mice received a single IN vaccination of naked or virosome-encapsulated
DNA encoding LUC. Luminescence was detected by the IVIS live imager
and quantified by Living Image software. (a) Empty pVAX vector, (b) 100mg
pVax LUC, (c) 20mg pVAX LUC, (d) Liposome plus 20mg pVAX LUC, E)
Virosome plus HA plus 20mg pVAX LUC. (B) The graph shows mean
photons s1 (±s.e.m.) and each point represents a single mouse.
Figure 2 Systemic and mucosal T-cell responses to LUC. IFN-g ELIspot was performed with cells restimulated with a single immunodominant LUC peptide.
SFU for cells from (a) spleens and (b) vaginal-draining lymph nodes from vaccinated mice. Graphs show mean SFU per 106 cells (±s.e.m.), and each point
represents a single mouse. Significant differences were determined by the Kruskal–Wallis multiple comparison test.
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shown); however, variability within groups was still observed. Live
imaging also showed that HA was necessary for effective delivery of
the DNA, as virosomes in which the HA was substituted with bovine
serum albumin failed to result in detectable luminescence (data not
shown). However, an IN boost with DNA in HAþ virosomes failed
to result in the expression of LUC, most likely because the mice
developed robust anti-HA antibody responses after the initial
vaccination (data not shown).
As a result of the failure of the IN boost to induce systemic and
mucosal immune responses to LUC, the mice received an IN prime
followed by two ID booster injections at 4-week intervals, and the
responses were compared with those after three ID injections.
The results of this experiment showed that mice that received the
3 ID injections developed a mean anti-LUC antibody titre of
1/6998 while the IN prime, 2 ID boost group developed a mean
titre of 1/2573, although this difference was not significant.
In contrast, the anti-LUC titre in the bronchial lavage from the
1 IN, 2 ID group was fourfold higher (1/11 vs 1/2.6) than that in
the 3 ID group while the titre in the vaginal lavage was
approximately twofold higher (1/7.5 vs 1/4). The cell-mediated
immune response was also examined by ELIspot analysis of inter-
feron-g-secreting cells in the splenocyte population and in cells
recovered from the vaginal-draining lymph nodes. There was no
significant difference in the systemic (splenocytes) responses induced
by 3 ID or 1 IN/2 ID regimens, (Figure 2a) whereas,
in contrast, mice which were vaccinated with the 1 IN/2 ID
regimen showed a significant increase in the frequency of interferon-
g-secreting cells in the lumbar and caudal/sacral lymph nodes
representing the vaginal-draining lymph nodes (Figure 2b). Cells
recovered from the draining lymph nodes around the nose (cervical)
were also examined, but these results were not significant. Thus, the
mucosal cell-mediated immunity was significantly higher (5.5-fold
after subtracting the background) in the 1 IN/2 ID vaccinated
mice compared with the 3 ID vaccination. Collectively, these data
show that the addition of HA to the virosomes was necessary to
deliver DNA to the mouse respiratory tract and an IN prime was
necessary to induce humoral and cell-mediated immunity in the
vaginal mucosa.
Expression of different genes that induce cell death results in
different cell death kinetics in vitro
As an alternative strategy to increase the efficacy of DNA vaccination,
we wished to compare the efficacy of several proteins that induce cell
Figure 3 A schematic diagram of the plasmid constructs. The constructs
were organised into three groups as noted in the figure. (a) TK constructs,
(b) cytolytic gene constructs in which the cytolytic gene expression was
controlled by the SV40 promoter and (c) cytolytic gene constructs in which
the cytolytic gene expression was controlled by the CMV promoter.
Figure 4 The induction of HEK293T cell death by cytolytic gene expression as determined by LUC expression. The cells were transfected with the different
DNA constructs as noted in a, b and c, and LUC expression used as a measure of cell viability compared with the control pVAX LUC. c was published
originally in reference number 21.
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death by different mechanisms when co-expressed with LUC as an
immunogen, to examine the hypothesis that lytic or necrotic cell
death would result in cross presentation of the immunogen and thus
increase the efficacy of vaccination. The herpes simplex virus
thymidine kinase (TK), the rotavirus non-structural protein 4
(NSP4),19 diphtheria toxin subunit A (DTa) and a modified form
of mouse perforin (PRF)20 were examined. A schematic of the
different constructs is shown in Figure 3. We have previously shown
that the SV40 promoter is 10-fold less efficient than the cytomega-
lovirus (CMV) promoter,21 while the foot and mouth disease virus 2A
protease self-cleaves resulting in equimolar concentrations of LUC
and PRF.
Initially, induced cell death was examined by LUC expression in
transfected cells and loss of LUC expression accepted as an indication
of cell death. As proof of concept, cells which were transfected with
DNA encoding LUC and TK± the addition of ganciclovir (GCV)
showed no evidence of cell death unless GCV was added to the
culture (Figure 4a). We then examined the effect of co-expression of
NSP4, DTa or PRF with LUC from constructs, which encoded the
cytolytic/apoptotic genes under the control of the SV40 promoter.
The results of this experiment showed that DTa was highly toxic as
levels of LUC were always low when compared with the control, so
that the luminescence was reduced by 90% at 48h post transfection
and none was detected at 72 h (Figure 4b). PRF reduced luminescence
by 50% at 48h and by 100% at 72h; however, the kinetics of LUC
expression differed markedly to that after co-expression of DTa. In
contrast, NSP4 showed little toxicity (Figure 4b). The effect of
expression of PRF from the CMV promoter, rather than the SV40
promoter was then examined; this showed that the kinetics of LUC
expression were similar to that after DTa expression (Figure 4c) and
confirmed that higher levels of PRF killed cells more rapidly.
The mechanism of cell death after cytolytic/apoptotic gene
expression in vitro
We then wished to determine the mechanism of cell death as it has
been suggested that necrotic cells are more immunogenic than
apoptotic cells.22 HEK 293 T cells were transfected with the
different DNA constructs and 72h later, cells that appeared in the
live and dead cell gates by flow cytometry were examined by Annexin
V and propidium iodide (PI) staining. The majority of cells in the
dead cell gate were Annexin Vþ, PIþ (Figure 5), whereas the majority
of cells in the live cell gate were Annexin V, PI. A proportion
(around 20%) of cells after transfection with each construct was
apoptotic, but a variable proportion, ranging from 32–60% was
considered to be necrotic (either Annexin Vþ PIþ or AnnexinV
PIþ ). This population is likely to represent secondary necrotic cells
that develop markers of necrosis in a time-dependent manner. The
staining revealed that, of the dead cells observed following
TK/GCV expression, 39% were apoptotic and 50% were necrotic,
whereas the NSP4 induced 28% apoptosis and 56% necrosis, PRF
induced 33 and 47%, respectively and DTa, 40 and 45%. The highest
proportions of dead cells were detected after transfection with plasmids,
which encoded PRF under the control of the CMV promoter. In
summary, the expression of NSP4 and PRF resulted in the highest
proportion of PIþ cells, suggesting necrotic or lytic cell death, whereas
DTa and TK/GCV preferentially induced apoptotic cell death.
The effect of cytolytic gene expression on LUC expression in vivo
To examine the effect of cytolytic/apoptotic gene expression on LUC
expression in vivo, the expression of LUC was examined in vaccinated
mice by live imaging. The efficacy of in vivo delivery of DNA encoding
LUC was first examined by direct imaging after ID injection of either
naked DNA or HAþ virosome-encapsulated DNA but no difference
was detected (data not shown), showing that naked DNA was equally
effective as virosome-encapsulated DNA in this setting. We therefore
decided to use naked DNA to conduct in vivo experiments to test the
effect of induction of cell death following DNA vaccination. In
contrast to the effect in vitro, expression of TK/GCV had no effect on
LUC expression, most likely because TK/GCV only kills actively
dividing cells (Figure 6a). DTa and PRF, however, accelerated the loss
of LUC-positive cells; DTa resulted in a 10-fold reduction in the initial
Figure 5 Markers of cell death after transfection of HEK293T cells with the
different DNA constructs, as determined by Annexin V and PI staining.
(a) The gating strategy for the Annexin V (x axes) and PI (y axes) staining
analysis. Two panels are shown for each construct; the left panel represents
cells in the dead cell gate and the right panel represents cells in the live
cell gate. (b) pVAX LUC, pVAX LUC TK, pVAX LUCþGCV and pVAX LUC
TKþGCV, (c) pVAX LUC NSP4, pVAX LUC PRF and pVAX LUC DTa
representing cytolytic genes expressed from the SV40 promoter and
(d) pVAX PRF LUC and pVAX LUC 2A PRF representing cytolytic genes
expressed from the CMV promoter.
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level of LUC expression and in a rapid loss of LUC-positive cells,
whereas PRF showed a slower loss (Figure 6b). Consistent with the
in vitro data, expression of PRF from the CMV promoter resulted in a
rapid loss of LUC-positive cells (Figure 6c).
The effect of cytolytic gene expression on the LUC-specific immune
response
The above results showed that expression of DTa and PRF from the
CMV promoter resulted in greater cell death than expression of NSP4
or TK (þGCV) and this might be expected to result in higher levels
of immune activation. To examine this, the LUC-specific immune
response was measured in vaccinated mice. The antibody response
was assessed by enzyme-linked immunosorbent assay, and, consistent
with the fact that TK/GCV had no effect on LUC expression,
expression of TK/GCV failed to increase the anti-LUC antibody titre
over that elicited by the canonical vaccine (Figure 7a). In contrast,
mice vaccinated with DNA encoding LUC PRF showed a trend
towards increased IgG titres, but this was not significant after
statistical analysis (Kruskal–Wallis and Wilcoxon post test;
Figure 7b). Mice vaccinated with the DTa construct developed
70-fold lower IgG titres than the control mice (Figure 7b), although
this difference was not statistically significant.
The cell-mediated immune responses were also measured by
stimulation of splenocytes with a C57BL/6 immunodominant LUC
peptide.23 The results of this analysis showed that expression of NSP4
and PRF (from the SV40 promoter) increased the cell-mediated
immune responses (Figures 7c and d), although the results were
not statistically significant, whereas expression of DTa and PRF (the
latter from the CMV promoter) resulted in a lower cell-mediated
response.
DISCUSSION
In this study, we examined two different strategies to increase the
efficacy of DNA vaccines. The first involved encapsulating the DNA in
HAþ virosomes, which bind to sialic acid receptors and deliver it to
respiratory epithelial cells after IN delivery. The second strategy
induced cell death in vaccine-targeted cells after ID vaccination by
the inclusion of a gene encoding cytolytic or toxic proteins in the
DNA vaccine and evaluated the resultant immune responses. The
uptake of viral antigen-positive dead or dying cells by DC and other
antigen-presenting cells represents a fundamental mechanism to elicit
immunity against pathogens that do not intrinsically infect DC and
we plan to exploit this natural mechanism to increase DNA vaccine
efficacy.
DNA contained in virosomes with HA embedded in the lipid
membrane was able to prime the immune system to elicit mucosal
humoral and cell-mediated immunity after ID booster injections. The
induced immune response to HA reflects the immunity induced to
recombinant virus vectors after multiple doses, necessitating the
development of heterologous vector vaccination regimens. However
the IN/ID regimen with a DNA vaccine, developed in this model
system, will overcome this limitation, and has the potential to elicit
robust mucosal immunity. Although the responses were low, LUC is
known to be a poor T-cell immunogen,24 and it is likely that the
responses to a more immunogenic protein will be higher. Our
IN/ID strategy is similar to an IN/intramuscular strategy described
previously.25
We also examined the ability of cytolytic or apoptotic genes to
increase the immune response to an immunogen encoded in a
bicistronic plasmid. We hypothesised that antigen-positive, necrotic
cells would release damage-associated molecular patterns along with
Figure 6 In vivo cell death as determined by LUC expression post vaccination. C57Bl/6 mice were vaccinated with 50mg DNA and luminescence detected
by IVIS imaging at intervals post vaccination. (a) pVAX LUC, pVAX LUC TK, pVAX LUCþGCV and pVAX LUC TKþGCV, (b) pVAX LUC NSP4, pVAX LUC
PRF and pVAX LUC DTa representing cytolytic genes expressed from the SV40 promoter and (c) pVAX PRF LUC and pVAX LUC 2A PRF representing
cytolytic genes expressed from the CMV promoter. Graphs show the mean luminescence±s.e.m. for five mice as measured by the IVIS live imager. c was
published originally in reference number 21.
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the antigen that would be phagocytosed by circulating DC and result
in cross presentation of the antigen and maturation of the DC. The
results of the study showed that, of the proteins controlled by the
SV40 promoter, NSP4 and PRF increased the immune responses to
LUC, whereas TK/GCV and DTa, and PRF driven from the CMV
promoter, either had no effect or decreased the immune responses.
The data suggest that there is a threshold of expression of the
immunogen that must be achieved before necrosis is induced in the
vaccine-targeted cells. As F-actin exposed on necrotic cells is
recognised by CLec9A on DC,26 it is likely that NSP4 and PRF
expression (from the SV40 promoter) increased the frequency of
cross-presenting DC and that this represented the mechanism of
increased immune responses. Furthermore, these studies with the
model antigen LUC provide a greater understanding of the effect of
different cytolytic proteins and we have shown that co-expression of
PRF with a highly immunogenic viral antigen, HIV gag,21 not only
resulted in increased levels of gag-specific cell-mediated immunity but
also in greater levels of protection against challenge with a chimeric
HIV, EcoHIV, that replicates in mice.21,27
Although the potential of DNA vaccines has not been realised in
humans, our previous studies21,28 and this study have outlined
different strategies to increase efficacy that might be combined in
the case of mucosal vaccines to elicit robust mucosal immunity. We
have also shown that PRF when co-expressed with the hepatitis C
virus NS3 protein results in greatly increased cell-mediated immune
responses in large adult pigs (Grubor-Bauk, in preparation),
suggesting that the strategy may be equally effective in humans.
METHODS
Virosome preparation
The virosomes were prepared essentially as described7 using the cationic lipid
DOTAP, with one major difference, as recombinant HA (Protein Sciences,
Meriden, CT, USA) rather than HA from egg-derived influenza virus was
added to the DNA–DOTAP suspension. The preparation was pelleted (30K
r.p.m., 1.5 h at 4 1C) on to a 50% sucrose cushion to remove free HA from
liposome-associated HA and the liposomes collected from the interface.
DNA vaccines
All DNA vaccines were prepared by standard molecular biology methods. The
vaccines were based on the plasmid pVAX (Invitrogen, Melbourne, VIC,
Australia) and encoded firefly LUC under the control of the CMV promoter.
DNA constructs (Figure 3) designed to induce cytolysis in vaccine-targeted
cells contained the LUC gene controlled by the CMV promoter, and various
cytolytic genes controlled by the SV40 promoter or alternatively as a LUC-
cytolytic polyprotein controlled by the CMV promoter that was designed to
autocleave by including the FMDV2a protease, essentially as described.21 The
constructs were sequenced to confirm authenticity and endotoxin-free
preparations were used for vaccination.
Vaccination and sample collection
Six to eight-week-old female C57Bl/6 mice, bred in specific pathogen-free
conditions, were purchased from the University of Adelaide and housed at the
Women’s and Children’s Hospital PC2 animal facility. Ethical approval was
obtained from the Women’s and Children’s Health Network and the University
of Adelaide Animal Ethics Committee. The mice were anaesthetised with
domitor/ketamine for all procedures. ID injections were performed by delivery
of the DNA to the ear. IN vaccination was performed by delivery of DNA in
Figure 7 Humoral and cell-mediated responses to LUC in mice vaccinated with the different DNA constructs. IgG titres were determined by enzyme-linked
immunosorbent assay in serum from mice vaccinated with (a) the LUC±TK constructs or (b) LUCþ the directly cytolytic genes. Graphs show mean
reciprocal IgG titre, ±s.e.m. IFN-g-secreting cells after restimulation of splenocytes with an immunodominant epitopes as detected by ELIspot in mice
vaccinated with (c) the LUC±TK constructs or (d) LUCþ the directly cytolytic genes. Graphs show meant SFU per 106 cells,±s.e.m.
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50ml saline essentially as described.29 Blood was collected by retro-orbital bleed.
Lavage samples were collected using phosphate-buffered saline containing
0.5mM phenylmethanesulfonyl fluoride as a wash. Vaginal lavage was
performed by inserting a pipette tip into the vaginal opening and repeatedly
pipetting a volume of 50ml in and out. Bronchial lavage was performed by
opening the skin covering the thorax, tying off the trachea and 50ml of
phosphate-buffered saline/phenylmethanesulfonyl fluoride injected into the
trachea. The lavage was collected in an eppendorf tube placed over the nose of
the mouse. Splenocytes were prepared as described21 and immunocytes from
draining lymph nodes were prepared in a similar manner, essentially by gentle
passage through a 70-mm cell strainer. The cells were resuspended in RPMI
culture media before analysis. Live imaging was performed using a Xenogen
IVIS 200 live imaging system (Caliper Life Sciences). The mice were injected
with D-luciferin either by the intraperitoneal route or by 50ml applied to the
nares, rested for 10min and then placed in the imaging chamber.
ELIspot
Briefly, 5 105 splenocytes were added to duplicate wells and stimulated with
4mgml1 LUC peptide for 40h at 37 1C, essentially as described.21 Spots were
formed by the addition of BCIP/NBT (Sigma, Castle Hill, NSW, Australia) and
left to develop in the dark for up to 30min. Plates were read on an AID EliSpot
Reader (Autoimmun Diagnostika, Strassberg, Germany) and analysed by the
AID EliSpot software (Autoimmun Diagnostika). The average number of spots
(spot-forming units; SFU) from the negative control was subtracted from each
stimulated sample and the data adjusted to SFU per 106 splenocytes.
Flow cytometry
To assess if suicide gene candidates induced necrosis or apoptosis, HEK293T
cells were plated in 24-well plates and transfected with plasmid DNA as
described above. Cells were collected at 72h time points and stained with
mouse Annexin V-FITC (BD #556420) and PI (BD #556463) according to the
BD staining protocol. Cells were analysed on a BD FACS Canto and analysed
with FlowJo software, essentially as described.21
Statistical analysis
Throughout the study, statistical analysis was performed by Kruskal–Wallis
multiple comparison with Wilcoxon post-tests, to allow for nonparametric
data and to correct for multiple comparisons. Data in graphs are presented as
the mean þ / s.e.m. Data analysis and generation of graphs were performed
using Graphpad Prism 5.0b and SAS Version 9.3, with assistance from the Data
Analysis and Management Centre, University of Adelaide. Nonparametric
Kruskal–Wallis test was used to compare the difference between the multiple
vaccine groups. If the global test showed significant difference between the
groups, then Wilcoxon tests were performed to compare the post hoc difference
between groups.
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